MedTrace Logo

Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT

NCT03575767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-10-04

No results posted yet for this study

Summary

Graft-versus-Host Disease (GVHD) and relapse, which is mainly due to lack of Graft-versus-Leukemia (GVL), are the most frequent and severe complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT). T cells expanded from mature T cells in the graft play a dominant role in development of GVHD and GVL early after allo-HSCT. Recent applications of high-throughput sequencing (HTS) to the T cells repertoire open a new avenue for us to look deeply into how these T cells dynamically adjust in the context of the recipient's environment.

The main goal of this research study is to set up a mathematical model based on T cell receptor (TCR) sequencing to enable prediction for the key immunologic outcomes early post-transplantation. This study will deepen the understanding of the molecular mechanisms driving the most deadly post-transplantation complications, and serve as convincing evidence upon which to choose a better donor and a more proper transplantation approach.

This observational trial will perform HTS for TCR β-chain complementarity determining region 3 (CDR3) repertoires of grafts and peripheral blood samples from recipients post-transplantation and analyze the relationship between dynamics of TCR CDR3 repertoires and clinical outcomes early post-transplantation, especially including GVHD and relapse. The investigators want to know how the antigen environment in recipients drives dynamics of mature T cells from grafts in order to use the new discovered rules to better predict and treat the disease process.

Conditions

  • Hematologic Neoplasms
  • Hematopoietic Stem Cell Transplantation
  • Graft Vs Host Disease
  • Recurrence

Interventions

OTHER

Myeloablative Hematopoietic Stem Cell Transplantation

Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.

Sponsors & Collaborators

  • Hangzhou ImmuQuad Biotechnologies, LLC

    collaborator UNKNOWN

  • Affiliated Hospital to Academy of Military Medical Sciences

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-08
Primary Completion
2018-08-20
Completion
2018-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575767 on ClinicalTrials.gov